Passage Bio (NASDAQ:PASG) Stock Breaks Above 50-Day Moving Average – What’s Next?

Passage Bio, Inc. (NASDAQ:PASG – Get Free Report)’s stock price crossed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $4.11 and traded as high as $4.25. Passage Bio shares last traded at $4.25, with a volume of 11,933 shares trading hands.

Analyst Ratings Changes

PASG has been the topic of several recent analyst reports. Weiss Ratings upgraded shares of Passage Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, November 2nd. Wall Street Zen downgraded shares of Passage Bio from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Two investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $13.25.

Read Our Latest Analysis on PASG

Passage Bio Stock Up 6.0%

The company has a 50 day moving average of $4.11 and a 200-day moving average of $5.87.

Passage Bio (NASDAQ:PASG – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($1.47) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.47). On average, analysts predict that Passage Bio, Inc. will post -7.75 EPS for the current fiscal year.

Institutional Investors Weigh In On Passage Bio

A number of large investors have recently made changes to their positions in PASG. Nantahala Capital Management LLC bought a new position in shares of Passage Bio during the third quarter valued at approximately $573,000. Renaissance Technologies LLC lifted its stake in Passage Bio by 22.5% in the first quarter. Renaissance Technologies LLC now owns 133,612 shares of the company’s stock worth $1,049,000 after acquiring an additional 24,523 shares during the period. Finally, Eversept Partners LP lifted its stake in Passage Bio by 4.2% in the first quarter. Eversept Partners LP now owns 131,581 shares of the company’s stock worth $1,033,000 after acquiring an additional 5,351 shares during the period. 53.48% of the stock is currently owned by institutional investors.

Passage Bio Company Profile

(Get Free Report)

Passage Bio is a clinical-stage biotechnology company developing gene therapies for rare, inherited central nervous system disorders. Its approach uses viral vectors to deliver genetic material intended to address the underlying causes of these diseases. The company’s lead program, PBFT02, is being developed for frontotemporal dementia associated with mutations in the GRN gene. Passage Bio has also worked on gene therapy candidates for other rare neurological conditions, including Krabbe disease and GM1 gangliosidosis.

Recommended Stories

Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter.